TCP is internationally recognized for leadership in pediatric clinical and translational pharmacology, pharmacometrics, quantitative proteomics, metabolomics, exposomics, physiologically based pharmacokinetic (PBPK) modeling, quantitative systems pharmacology (QSP), environmental health sciences, model-informed precision dosing (MIPD), and model-informed drug development (MIDD). Research programs that integrate exposomics, proteomics, metabolomics, human-relevant New Approach Methodologies (NAMs), patient-derived organoids, microphysiological systems, and real-world clinical data with AI/ML-enabled predictive frameworks are particularly encouraged.